Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies

41 BIOTECHNOLOGY LAW REPORT 269 (2022)

21 Pages Posted: 8 Mar 2023

See all articles by Christopher M. Holman

Christopher M. Holman

University of Missouri - Kansas City School of Law

Date Written: November 4, 2022

Abstract

On November 4, 2022, the U. S. Supreme Court granted certiorari in the case of Amgen v. Sanofi. This is the first time that the Court has addressed patent laws enablement requirement, or for that matter any of the adequate disclosure requirements of 35 USC 112(a), i.e., the written description and best mode requirements, since the enactment of the Patent Act of 1952. This article summarize the Federal Circuit decision that is the subject of the grant of certiorari, and then delve into some of the main arguments that were raised in Amgen’s petition for certiorari; Sanofi’s brief in opposition to grant of certiorari; GlaxoSmithKline’s amicus curiae brief supporting grant of certiorari; an amici curiae brief supporting grant of certiorari follow behalf of a coalition including Association of University Technology Transfer Managers, Biogen, Bristol-Myers Squibb, Corning Inc., MerckSharp & Dohme, and St. Jude Children’s Research Hospital; and an amicus curiae brief filed on behalf of the U. S. government by the Solicitor General recommending that the Court not grant certiorari.

Keywords: patents, enablement, pharmaceuticals, Amgen, Sanofi, Supreme Court

Suggested Citation

Holman, Christopher M., Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies (November 4, 2022). 41 BIOTECHNOLOGY LAW REPORT 269 (2022), Available at SSRN: https://ssrn.com/abstract=4378377

Christopher M. Holman (Contact Author)

University of Missouri - Kansas City School of Law ( email )

5100 Rockhill Road
Kansas City, MO 64110-2499
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
78
Abstract Views
657
Rank
509,576
PlumX Metrics